These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Donor lymphocyte infusions as primary therapy for neoplasms. Montefusco V Blood; 2003 Jan; 101(1):373; author reply 373-4. PubMed ID: 12485941 [No Abstract] [Full Text] [Related]
63. Defining a TCF1-expressing progenitor allogeneic CD8 Lee S; Lee K; Bae H; Lee K; Lee J; Ma J; Lee YJ; Lee BR; Park WY; Im SJ Nat Commun; 2023 Sep; 14(1):5869. PubMed ID: 37737221 [TBL] [Abstract][Full Text] [Related]
64. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Chakraverty R; Sykes M Blood; 2007 Jul; 110(1):9-17. PubMed ID: 17327406 [TBL] [Abstract][Full Text] [Related]
65. Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions. Hoevenaren IA; van Vulpen LF; Levenga H; Minnema MC; Raymakers R Bone Marrow Transplant; 2011 Feb; 46(2):319-21. PubMed ID: 20305701 [No Abstract] [Full Text] [Related]
66. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296 [TBL] [Abstract][Full Text] [Related]
71. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]